Advent International has outbid KKR in a private equity bidding war for Spectris after the UK industrial group accepted its ...

Advent International said it increased its takeover bid for precision-measurement company Spectris to 4.2 billion pounds ($5.55 billion).

Precision instrument maker Spectris has agreed to be bought by Advent International after it trumped an offer from US ...

British scientific instruments maker Spectris SXS.L has agreed to private equity firm Advent's sweetened takeover offer worth ...

Advent’s increased offer represents a 2.5 percent increase to the KKR offer. This means the shareholders will receive an additional £1.00 per share, amounting to a total increase of £101.5 million ...

British scientific instruments maker Spectris has agreed to private equity firm Advent's sweetened takeover bid valued at 4.8 billion pounds ($6.38 billion), including debt, the companies said on ...

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

The firm is acting for the Just Group in its £2.4 billion sale, a month after it helped conclude the sale of Spectris to a ...

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease ...

Spectris' Earnings Growth And 10% ROE To begin with, Spectris seems to have a respectable ROE. Even when compared to the industry average of 10% the company's ROE looks quite decent.

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

Although Spectris reported robust trading across the globe, performance was strongest in its Asia Pacific business, where sales jumped 17 per cent on a like-for-like basis.